WallStreetZenWallStreetZen

NASDAQ: ROIV
Roivant Sciences Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ROIV

Based on 1 analyst offering 12 month price targets for Roivant Sciences Ltd

Min Forecast
$18.00+63.49%
Avg Forecast
$18.00+63.49%
Max Forecast
$18.00+63.49%

Should I buy or sell ROIV stock?

Based on 1 analyst offering ratings for Roivant Sciences Ltd.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ROIV's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ROIV as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ROIV stock forecasts and price targets.

ROIV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-21

1 of 1

Forecast return on equity

Is ROIV forecast to generate an efficient return?

Company
N/A
Industry
144.6%
Market
80.02%

Forecast return on assets

Is ROIV forecast to generate an efficient return on assets?

Company
N/A
Industry
35.78%

ROIV earnings per share forecast

What is ROIV's earnings per share in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.30

ROIV revenue forecast

What is ROIV's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$28.5M-70.75%
Avg 2 year Forecast
$73.5M-24.66%
Avg 3 year Forecast
$1.0B+935.19%
ROIV's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ROIV revenue growth forecast

How is ROIV forecast to perform vs Biotechnology companies and vs the US market?

Company
97.82%
Industry
64.34%
Market
10.27%
ROIV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ROIV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ROIV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ROIV$11.01$18.00+63.49%Buy
TECH$50.24$78.83+56.91%Buy
CORT$71.71$143.25+99.76%Strong Buy
HALO$60.49$64.67+6.91%Buy
MDGL$326.79$398.80+22.04%Buy
View Top Biotech Stocks

Roivant Sciences Stock Forecast FAQ

Is Roivant Sciences Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ROIV) stock is to Buy ROIV stock.

Out of 1 analyst, 0 (0%) are recommending ROIV as a Strong Buy, 1 (100%) are recommending ROIV as a Buy, 0 (0%) are recommending ROIV as a Hold, 0 (0%) are recommending ROIV as a Sell, and 0 (0%) are recommending ROIV as a Strong Sell.

If you're new to stock investing, here's how to buy Roivant Sciences stock.

What is ROIV's earnings growth forecast for 2026-2026?

(NASDAQ: ROIV) Roivant Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.58%.

Roivant Sciences's earnings in 2025 is -$219,233,000.

In 2026, ROIV is forecast to generate -$925,259,582 in earnings, with the lowest earnings forecast at -$1,127,408,144 and the highest earnings forecast at -$734,955,942.

What is ROIV's revenue growth forecast for 2026-2028?

(NASDAQ: ROIV) Roivant Sciences's forecast annual revenue growth rate of 97.82% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.27%.

Roivant Sciences's revenue in 2025 is $97,555,000.On average, 4 Wall Street analysts forecast ROIV's revenue for 2026 to be $20,357,566,037, with the lowest ROIV revenue forecast at $5,080,472,141, and the highest ROIV revenue forecast at $42,812,967,480. On average, 4 Wall Street analysts forecast ROIV's revenue for 2027 to be $52,442,317,416, with the lowest ROIV revenue forecast at $17,125,186,992, and the highest ROIV revenue forecast at $111,313,715,448.

In 2028, ROIV is forecast to generate $720,595,758,898 in revenue, with the lowest revenue forecast at $398,874,147,022 and the highest revenue forecast at $1,042,317,370,774.

What is ROIV's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ROIV) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 35.78%.

What is ROIV's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ROIV price target, the average ROIV price target is $18.00, with the highest ROIV stock price forecast at $18.00 and the lowest ROIV stock price forecast at $18.00.

The Wall Street analyst predicted that Roivant Sciences's share price could reach $18.00 by Apr 21, 2026. The average Roivant Sciences stock price prediction forecasts a potential upside of 63.49% from the current ROIV share price of $11.01.

What is ROIV's Earnings Per Share (EPS) forecast for 2026-2026?

(NASDAQ: ROIV) Roivant Sciences's current Earnings Per Share (EPS) is -$0.19. In 2026, ROIV's EPS is forecast to hit -$1.30 (min: -$1.58, max: -$1.03).

What is ROIV's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ROIV) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.